Rapid Response to Mycophenolate Mofetil in Combination with Romiplostim in a Case of Severe Refractory Immune Thrombocytopenia Post COVID-19 Vaccination

Authors

Snigdha Nutalapati, University of KentuckyFollow
Garima Gupta, University of KentuckyFollow
Gerhard C. Hildebrandt, University of KentuckyFollow

Abstract

Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.

Document Type

Article

Publication Date

11-6-2021

Notes/Citation Information

Published in Clinical Case Reports, v. 9, issue 11, e05035.

© 2021 The Authors

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Digital Object Identifier (DOI)

https://doi.org/10.1002/ccr3.5035

Repository Citation

Nutalapati, Snigdha; Gupta, Garima; and Hildebrandt, Gerhard C., "Rapid Response to Mycophenolate Mofetil in Combination with Romiplostim in a Case of Severe Refractory Immune Thrombocytopenia Post COVID-19 Vaccination" (2021). Internal Medicine Faculty Publications. 267.
https://uknowledge.uky.edu/internalmedicine_facpub/267